What does FDA approval of Vera’s Trutakna mean for the IgAN market?

The FDA has cleared Vera Therapeutics’ Trutakna (atacicept) as the sixth approved therapy for IgA nephropathy, marking the company’s shift from development to commercialization. Its success will depend on differentiation in efficacy, safety, and renal outcomes amid growing competition from Novartis, Otsuka, and other biologics in the crowded IgAN space.